Silver Book Fact

Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.

Black D, Thompson D, Bauer D, et al. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial. J Clin Endocrinol Metabo. 2000; 85(11): 4118-24. http://jcem.endojournals.org/cgi/content/full/85/11/4118

Reference

Title
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial
Publication
J Clin Endocrinol Metabo
Publication Date
2000
Authors
Black D, Thompson D, Bauer D, et al
Volume & Issue
Volume 85, Issue 11
Pages
4118-24
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.